BIO Valuation Metrics
BIO Stock Price Metrics
BIO Dividend Metrics
BIO Growth Rate Metrics
BIO Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
BIO Revenue Metrics
BIO PE Ratio Metrics
| PE Ratio | 50.22 |
| PE Ratio Avg TTM | 20.47 |
| PE Ratio Avg 3Y | 8.38 |
| Current VS TTM Avg | +145.38% |
| Current VS 3Y Avg | +499.60% |
| Current VS 5Y Avg | +668.95% |
BIO PS Ratio Metrics
| PS Ratio | 3.17 |
| PS Ratio Avg TTM | 3.02 |
| PS Ratio Avg 3Y | 3.31 |
| Current VS TTM Avg | +5.08% |
| Current VS 3Y Avg | -4.30% |
| Current VS 5Y Avg | -26.87% |
BIO PB Ratio Metrics
| PB Ratio | 1.20 |
| PB Ratio Avg TTM | 1.11 |
| PB Ratio Avg 3Y | 1.14 |
| Current VS TTM Avg | +8.26% |
| Current VS 3Y Avg | +5.64% |
| Current VS 5Y Avg | -7.44% |
BIO Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 23.01 |
| PFCF Ratio Avg TTM | 22.22 |
| PFCF Ratio Avg 3Y | 39.72 |
| Current VS TTM Avg | +3.54% |
| Current VS 3Y Avg | -42.07% |
| Current VS 5Y Avg | -51.67% |
BIO Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.21 |
| Debt/Equity Ratio Avg TTM | 0.21 |
| Debt/Equity Ratio Avg 3Y | 0.18 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | +16.67% |
| Current VS 5Y Avg | +65.79% |
BIO PEG Ratio Metrics
| PEG Ratio | 0.18 |
| PEG Ratio Avg TTM | 0.18 |
| PEG Ratio Avg 3Y | 0.18 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
BIO FCF Yield
| FCF Yield | 4.35% |
| FCF Yield Avg TTM | 4.55% |
| FCF Yield Avg 3Y | 3.09% |
| Current VS TTM Avg | -4.33% |
| Current VS 3Y Avg | +40.87% |
| Current VS 5Y Avg | +56.57% |
BIO Earnings Yield
| Earnings Yield | 1.99% |
| Earnings Yield Avg TTM | 13.62% |
| Earnings Yield Avg 3Y | 34.28% |
| Current VS TTM Avg | -85.39% |
| Current VS 3Y Avg | -94.20% |
| Current VS 5Y Avg | -93.72% |
BIO EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 37.95 |
| Ev/Ebit Ratio Avg TTM | 37.86 |
| Ev/Ebit Ratio Avg 3Y | 32.78 |
| Current VS TTM Avg | +0.25% |
| Current VS 3Y Avg | +15.78% |
| Current VS 5Y Avg | +13.99% |
BIO EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 262.68 |
| Ev/Ebitda Ratio Avg TTM | 52.45 |
| Ev/Ebitda Ratio Avg 3Y | 101.26 |
| Current VS TTM Avg | +400.86% |
| Current VS 3Y Avg | +159.42% |
| Current VS 5Y Avg | +325.45% |
BIO EV/Assets Ratio Metrics
| Ev/Assets Ratio | 0.93 |
| Ev/Assets Ratio Avg TTM | 0.87 |
| Ev/Assets Ratio Avg 3Y | 0.89 |
| Current VS TTM Avg | +6.67% |
| Current VS 3Y Avg | +4.57% |
| Current VS 5Y Avg | -6.45% |
BIO EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.51 |
| Ev/Sales Ratio Avg TTM | 3.40 |
| Ev/Sales Ratio Avg 3Y | 3.68 |
| Current VS TTM Avg | +3.37% |
| Current VS 3Y Avg | -4.61% |
| Current VS 5Y Avg | -23.49% |
BIO Current Ratio Metrics
| Current Ratio | 5.62 |
| Current Ratio Avg TTM | 6.05 |
| Current Ratio Avg 3Y | 5.87 |
| Current VS TTM Avg | -7.11% |
| Current VS 3Y Avg | -4.26% |
| Current VS 5Y Avg | +13.19% |
BIO Quick Ratio Metrics
| Quick Ratio | 4.19 |
| Quick Ratio Avg TTM | 4.52 |
| Quick Ratio Avg 3Y | 4.42 |
| Current VS TTM Avg | -7.30% |
| Current VS 3Y Avg | -5.15% |
| Current VS 5Y Avg | +13.50% |
BIO ROIC Metrics
| ROIC | 2.04% |
| ROIC Avg 3Y | 2.35% |
| ROIC Avg 5Y | 2.39% |
| Current VS 3Y Avg | -13.38% |
| Current VS 5Y Avg | -14.64% |
| Current VS 10Y Avg | -3.73% |
BIO Return on Assets Metrics
| ROA | 7.18 |
| ROA Avg TTM | (6.26) |
| ROA Avg 3Y | (11.14) |
| Current VS TTM Avg | -214.79% |
| Current VS 3Y Avg | -164.45% |
| Current VS 5Y Avg | +392.91% |
BIO Return on Equity Metrics
| ROE | 10.20 |
| ROE Avg TTM | (8.94) |
| ROE Avg 3Y | (15.72) |
| Current VS TTM Avg | -214.16% |
| Current VS 3Y Avg | -164.88% |
| Current VS 5Y Avg | +798.68% |
BIO Net Profit Margin Metrics
| Net Profit Margin | 29.42% |
| Net Profit Margin Avg TTM | (21.22%) |
| Net Profit Margin Avg 3Y | (48.94%) |
| Current VS TTM Avg | -238.64% |
| Current VS 3Y Avg | -160.12% |
| Current VS 5Y Avg | +77.14% |
Last Updated: Tuesday, June 9, 2026
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz